ID   PNCB_HUMAN              Reviewed;         538 AA.
AC   Q6XQN6; A7BFI3; Q6PJL1; Q6XQN4; Q6XQN5; Q8N5E8; Q9BRG0;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   15-JAN-2008, sequence version 2.
DT   15-MAR-2017, entry version 111.
DE   RecName: Full=Nicotinate phosphoribosyltransferase;
DE            Short=NAPRTase;
DE            EC=6.3.4.21;
DE   AltName: Full=FHA-HIT-interacting protein;
DE   AltName: Full=Nicotinate phosphoribosyltransferase domain-containing protein 1;
GN   Name=NAPRT; Synonyms=FHIP, NAPRT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=17604275; DOI=10.1074/jbc.M610357200;
RA   Hara N., Yamada K., Shibata T., Osago H., Hashimoto T., Tsuchiya M.;
RT   "Elevation of cellular NAD levels by nicotinic acid and involvement of
RT   nicotinic acid phosphoribosyltransferase in human cells.";
RL   J. Biol. Chem. 282:24574-24582(2007).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3).
RA   Huang C.-H., Chen H., Chen Y.;
RT   "Identification of nicotinate phosphoribosyltransferase as a novel
RT   FHA-HIT interaction protein (FHIP).";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-537, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [5]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-537, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-537, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-537, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-537, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [10]
RP   BIOPHYSICOCHEMICAL PROPERTIES, CHARACTERIZATION, 3D-STRUCTURE
RP   MODELING, AND MUTAGENESIS OF ASP-19; TYR-21; GLY-169; GLY-209;
RP   HIS-213; ASP-288; ARG-318; ASN-357; GLY-379; THR-380 AND SER-381.
RX   PubMed=21742010; DOI=10.1016/j.biochi.2011.06.033;
RA   Galassi L., Di Stefano M., Brunetti L., Orsomando G., Amici A.,
RA   Ruggieri S., Magni G.;
RT   "Characterization of human nicotinate phosphoribosyltransferase:
RT   Kinetic studies, structure prediction and functional analysis by site-
RT   directed mutagenesis.";
RL   Biochimie 94:300-309(2012).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-537, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
CC   -!- FUNCTION: Catalyzes the conversion of nicotinic acid (NA) to NA
CC       mononucleotide (NaMN). Essential for NA to increase cellular NAD
CC       levels and prevent oxidative stress of the cells.
CC       {ECO:0000269|PubMed:17604275}.
CC   -!- FUNCTION: Catalyzes the synthesis of beta-nicotinate D-
CC       ribonucleotide from nicotinate and 5-phospho-D-ribose 1-phosphate
CC       at the expense of ATP. {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: Nicotinate + 5-phospho-alpha-D-ribose 1-
CC       diphosphate + ATP + H(2)O = beta-nicotinate D-ribonucleotide +
CC       diphosphate + ADP + phosphate.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=44.3 uM for nicotinic acid (in the presence of 3 mM ATP)
CC         {ECO:0000269|PubMed:21742010};
CC         KM=22.1 uM for 5-phosphoribosyl-1-pyrophosphate (in the presence
CC         of 3 mM ATP) {ECO:0000269|PubMed:21742010};
CC         KM=27.3 uM for nicotinic acid (in the presence of inorganic
CC         phosphate) {ECO:0000269|PubMed:21742010};
CC         KM=38.2 uM for 5-phosphoribosyl-1-pyrophosphate (in the presence
CC         of inorganic phosphate) {ECO:0000269|PubMed:21742010};
CC   -!- PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; nicotinate D-
CC       ribonucleotide from nicotinate: step 1/1.
CC   -!- INTERACTION:
CC       Q2TAC2:CCDC57; NbExp=3; IntAct=EBI-10254820, EBI-2808286;
CC       A2ABF9:EHMT2; NbExp=3; IntAct=EBI-10254820, EBI-10174566;
CC       Q96HH9:GRAMD3; NbExp=3; IntAct=EBI-10254872, EBI-2832937;
CC       Q6A162:KRT40; NbExp=3; IntAct=EBI-10254820, EBI-10171697;
CC       Q93062:RBPMS; NbExp=3; IntAct=EBI-10254872, EBI-740322;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:17604275}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q6XQN6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6XQN6-2; Sequence=VSP_030612;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q6XQN6-3; Sequence=VSP_030610;
CC         Note=No experimental confirmation available.;
CC   -!- SIMILARITY: Belongs to the NAPRTase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH06284.2; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAH32466.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB242230; BAF75377.1; -; mRNA.
DR   EMBL; AY214325; AAP69603.1; -; mRNA.
DR   EMBL; AY214326; AAP69604.1; -; mRNA.
DR   EMBL; AY214327; AAP69605.1; -; mRNA.
DR   EMBL; BC006284; AAH06284.2; ALT_INIT; mRNA.
DR   EMBL; BC032466; AAH32466.1; ALT_INIT; mRNA.
DR   CCDS; CCDS6403.2; -. [Q6XQN6-1]
DR   CCDS; CCDS69555.1; -. [Q6XQN6-3]
DR   RefSeq; NP_001273758.1; NM_001286829.1. [Q6XQN6-3]
DR   RefSeq; NP_660202.3; NM_145201.5. [Q6XQN6-1]
DR   RefSeq; XP_016869469.1; XM_017013980.1.
DR   UniGene; Hs.493164; -.
DR   PDB; 4YUB; X-ray; 2.90 A; A/B=1-538.
DR   PDBsum; 4YUB; -.
DR   ProteinModelPortal; Q6XQN6; -.
DR   SMR; Q6XQN6; -.
DR   BioGrid; 125001; 35.
DR   IntAct; Q6XQN6; 6.
DR   STRING; 9606.ENSP00000401508; -.
DR   iPTMnet; Q6XQN6; -.
DR   PhosphoSitePlus; Q6XQN6; -.
DR   DMDM; 166221824; -.
DR   EPD; Q6XQN6; -.
DR   MaxQB; Q6XQN6; -.
DR   PaxDb; Q6XQN6; -.
DR   PeptideAtlas; Q6XQN6; -.
DR   PRIDE; Q6XQN6; -.
DR   Ensembl; ENST00000426292; ENSP00000390949; ENSG00000147813. [Q6XQN6-3]
DR   Ensembl; ENST00000449291; ENSP00000401508; ENSG00000147813. [Q6XQN6-1]
DR   Ensembl; ENST00000621955; ENSP00000480017; ENSG00000278488. [Q6XQN6-1]
DR   Ensembl; ENST00000632139; ENSP00000488794; ENSG00000278488. [Q6XQN6-3]
DR   GeneID; 93100; -.
DR   KEGG; hsa:93100; -.
DR   UCSC; uc003yym.6; human. [Q6XQN6-1]
DR   CTD; 93100; -.
DR   DisGeNET; 93100; -.
DR   GeneCards; NAPRT; -.
DR   HGNC; HGNC:30450; NAPRT.
DR   HPA; CAB068206; -.
DR   HPA; CAB068207; -.
DR   HPA; HPA023739; -.
DR   HPA; HPA024017; -.
DR   MIM; 611552; gene.
DR   neXtProt; NX_Q6XQN6; -.
DR   OpenTargets; ENSG00000147813; -.
DR   PharmGKB; PA142671293; -.
DR   eggNOG; KOG2511; Eukaryota.
DR   eggNOG; COG1488; LUCA.
DR   GeneTree; ENSGT00390000002664; -.
DR   HOVERGEN; HBG062439; -.
DR   InParanoid; Q6XQN6; -.
DR   KO; K00763; -.
DR   OMA; HSYVEAF; -.
DR   OrthoDB; EOG091G088G; -.
DR   PhylomeDB; Q6XQN6; -.
DR   TreeFam; TF314732; -.
DR   BRENDA; 6.3.4.21; 2681.
DR   Reactome; R-HSA-197264; Nicotinamide salvaging.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   UniPathway; UPA00253; UER00457.
DR   ChiTaRS; FAM160A2; human.
DR   GenomeRNAi; 93100; -.
DR   PRO; PR:Q6XQN6; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000147813; -.
DR   CleanEx; HS_NAPRT1; -.
DR   ExpressionAtlas; Q6XQN6; baseline and differential.
DR   Genevisible; Q6XQN6; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0016874; F:ligase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004516; F:nicotinate phosphoribosyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0004514; F:nicotinate-nucleotide diphosphorylase (carboxylating) activity; IEA:InterPro.
DR   GO; GO:0034356; P:NAD biosynthesis via nicotinamide riboside salvage pathway; TAS:Reactome.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0019358; P:nicotinate nucleotide salvage; IEA:InterPro.
DR   GO; GO:0006979; P:response to oxidative stress; IMP:UniProtKB.
DR   InterPro; IPR007229; Nic_PRibTrfase-Fam.
DR   InterPro; IPR006405; Nic_PRibTrfase_pncB.
DR   InterPro; IPR002638; Quinolinate_PRibosylTrfase_C.
DR   PANTHER; PTHR11098; PTHR11098; 1.
DR   PIRSF; PIRSF000484; NAPRT; 1.
DR   SUPFAM; SSF51690; SSF51690; 2.
DR   TIGRFAMs; TIGR01513; NAPRTase_put; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome; Cytoplasm;
KW   Ligase; Phosphoprotein; Polymorphism;
KW   Pyridine nucleotide biosynthesis; Reference proteome; Transferase.
FT   CHAIN         1    538       Nicotinate phosphoribosyltransferase.
FT                                /FTId=PRO_0000315681.
FT   MOD_RES     537    537       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ     469    481       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_030610.
FT   VAR_SEQ     517    517       Y -> YQVGGGGPPCHSALCAPALTLPTAPVLCSL (in
FT                                isoform 2). {ECO:0000303|Ref.2}.
FT                                /FTId=VSP_030612.
FT   VARIANT      57     57       A -> V (in dbSNP:rs896950).
FT                                /FTId=VAR_038275.
FT   MUTAGEN      19     19       D->A: Complete loss of activity.
FT                                {ECO:0000269|PubMed:21742010}.
FT   MUTAGEN      21     21       Y->A: Partial loss of activity in the
FT                                presence of ATP, complete loss in the
FT                                absence of ATP.
FT                                {ECO:0000269|PubMed:21742010}.
FT   MUTAGEN     169    169       G->A: Partial loss of activity.
FT                                {ECO:0000269|PubMed:21742010}.
FT   MUTAGEN     209    209       G->A: Partial loss of activity.
FT                                {ECO:0000269|PubMed:21742010}.
FT   MUTAGEN     213    213       H->A: Partial loss of activity.
FT                                {ECO:0000269|PubMed:21742010}.
FT   MUTAGEN     288    288       D->A: Partial loss of activity.
FT                                {ECO:0000269|PubMed:21742010}.
FT   MUTAGEN     318    318       R->A: Partial loss of activity in the
FT                                presence of ATP, almost complete loss in
FT                                the absence of ATP.
FT                                {ECO:0000269|PubMed:21742010}.
FT   MUTAGEN     357    357       N->A: Small loss of activity.
FT                                {ECO:0000269|PubMed:21742010}.
FT   MUTAGEN     379    379       G->A: Complete loss of activity.
FT                                {ECO:0000269|PubMed:21742010}.
FT   MUTAGEN     380    380       T->A: Partial loss of activity.
FT                                {ECO:0000269|PubMed:21742010}.
FT   MUTAGEN     381    381       S->A: Partial loss of activity.
FT                                {ECO:0000269|PubMed:21742010}.
FT   CONFLICT    155    155       L -> V (in Ref. 2; AAP69603/AAP69604/
FT                                AAP69605). {ECO:0000305}.
FT   CONFLICT    224    224       V -> A (in Ref. 1; BAF75377).
FT                                {ECO:0000305}.
FT   CONFLICT    246    246       A -> T (in Ref. 1; BAF75377).
FT                                {ECO:0000305}.
FT   CONFLICT    375    375       V -> A (in Ref. 1; BAF75377).
FT                                {ECO:0000305}.
FT   HELIX        20     31       {ECO:0000244|PDB:4YUB}.
FT   STRAND       35     44       {ECO:0000244|PDB:4YUB}.
FT   HELIX        49     51       {ECO:0000244|PDB:4YUB}.
FT   HELIX        60     66       {ECO:0000244|PDB:4YUB}.
FT   HELIX        74     79       {ECO:0000244|PDB:4YUB}.
FT   HELIX        89     91       {ECO:0000244|PDB:4YUB}.
FT   HELIX        96     98       {ECO:0000244|PDB:4YUB}.
FT   STRAND      105    108       {ECO:0000244|PDB:4YUB}.
FT   STRAND      121    127       {ECO:0000244|PDB:4YUB}.
FT   HELIX       128    133       {ECO:0000244|PDB:4YUB}.
FT   HELIX       135    159       {ECO:0000244|PDB:4YUB}.
FT   STRAND      166    168       {ECO:0000244|PDB:4YUB}.
FT   HELIX       178    189       {ECO:0000244|PDB:4YUB}.
FT   STRAND      192    195       {ECO:0000244|PDB:4YUB}.
FT   HELIX       197    203       {ECO:0000244|PDB:4YUB}.
FT   HELIX       213    216       {ECO:0000244|PDB:4YUB}.
FT   STRAND      233    237       {ECO:0000244|PDB:4YUB}.
FT   HELIX       242    257       {ECO:0000244|PDB:4YUB}.
FT   HELIX       266    278       {ECO:0000244|PDB:4YUB}.
FT   HELIX       280    282       {ECO:0000244|PDB:4YUB}.
FT   STRAND      283    286       {ECO:0000244|PDB:4YUB}.
FT   TURN        292    295       {ECO:0000244|PDB:4YUB}.
FT   HELIX       296    306       {ECO:0000244|PDB:4YUB}.
FT   TURN        307    310       {ECO:0000244|PDB:4YUB}.
FT   STRAND      314    319       {ECO:0000244|PDB:4YUB}.
FT   HELIX       324    342       {ECO:0000244|PDB:4YUB}.
FT   HELIX       345    348       {ECO:0000244|PDB:4YUB}.
FT   STRAND      351    354       {ECO:0000244|PDB:4YUB}.
FT   HELIX       360    366       {ECO:0000244|PDB:4YUB}.
FT   STRAND      375    377       {ECO:0000244|PDB:4YUB}.
FT   STRAND      394    400       {ECO:0000244|PDB:4YUB}.
FT   STRAND      421    427       {ECO:0000244|PDB:4YUB}.
FT   STRAND      429    431       {ECO:0000244|PDB:4YUB}.
FT   STRAND      433    440       {ECO:0000244|PDB:4YUB}.
FT   STRAND      451    454       {ECO:0000244|PDB:4YUB}.
FT   STRAND      463    465       {ECO:0000244|PDB:4YUB}.
FT   STRAND      468    472       {ECO:0000244|PDB:4YUB}.
FT   STRAND      475    479       {ECO:0000244|PDB:4YUB}.
FT   HELIX       490    503       {ECO:0000244|PDB:4YUB}.
FT   HELIX       506    509       {ECO:0000244|PDB:4YUB}.
FT   STRAND      511    513       {ECO:0000244|PDB:4YUB}.
FT   STRAND      518    522       {ECO:0000244|PDB:4YUB}.
FT   HELIX       523    529       {ECO:0000244|PDB:4YUB}.
SQ   SEQUENCE   538 AA;  57578 MW;  26DF39885CBB1C9B CRC64;
     MAAEQDPEAR AAARPLLTDL YQATMALGYW RAGRARDAAE FELFFRRCPF GGAFALAAGL
     RDCVRFLRAF RLRDADVQFL ASVLPPDTDP AFFEHLRALD CSEVTVRALP EGSLAFPGVP
     LLQVSGPLLV VQLLETPLLC LVSYASLVAT NAARLRLIAG PEKRLLEMGL RRAQGPDGGL
     TASTYSYLGG FDSSSNVLAG QLRGVPVAGT LAHSFVTSFS GSEVPPDPML APAAGEGPGV
     DLAAKAQVWL EQVCAHLGLG VQEPHPGERA AFVAYALAFP RAFQGLLDTY SVWRSGLPNF
     LAVALALGEL GYRAVGVRLD SGDLLQQAQE IRKVFRAAAA QFQVPWLESV LIVVSNNIDE
     EALARLAQEG SEVNVIGIGT SVVTCPQQPS LGGVYKLVAV GGQPRMKLTE DPEKQTLPGS
     KAAFRLLGSD GSPLMDMLQL AEEPVPQAGQ ELRVWPPGAQ EPCTVRPAQV EPLLRLCLQQ
     GQLCEPLPSL AESRALAQLS LSRLSPEHRR LRSPAQYQVV LSERLQALVN SLCAGQSP
//
